Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers... Current Clinical Issues Guideline Summary American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer line with the ASCO guideline for follow-up and management of Context patients with breast cancer. ASCO convened an expert panel to produce this 2007 update of its recommendations for the use of tumor markers in breast cancer. The previous guideline on this topic was published The recommendation for monitoring patients with metastatic in 2001. disease during active therapy with CA27.29 or CA15-3 used in conjunction with diagnostic imaging, history, and physical examination has not changed. Updated 2007 Recommendations CEA Table A1 (online-only supplement; also available at CEA levels increase less commonly than MUC-1 levels. Data www.asco.org/guidelines/breasttm) presents a complete suggest that evaluating one of the MUC-1 assays and also CEA summary of the updated recommendations. initially in a patient with metastatic disease is reasonable. If the MUC-1 assay is elevated, monitoring CEA has no role, but if not, then CEA levels may provide supplementary clinical Breast Cancer Tumor Markers information for monitoring response to treatment as long as it is The panel considered evidence regarding 13 categories of breast done with clinical and radiographic investigations. tumor http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Oncology Practice Wolters Kluwer Health

American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

Journal of Oncology Practice , Volume 3 (6) – Nov 1, 2007

Loading next page...
 
/lp/wolters-kluwer-health/american-society-of-clinical-oncology-2007-update-of-recommendations-K0n3MOpIVE

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright (C) 2007 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1554-7477
DOI
10.1200/JOP.0768504
Publisher site
See Article on Publisher Site

Abstract

Current Clinical Issues Guideline Summary American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer line with the ASCO guideline for follow-up and management of Context patients with breast cancer. ASCO convened an expert panel to produce this 2007 update of its recommendations for the use of tumor markers in breast cancer. The previous guideline on this topic was published The recommendation for monitoring patients with metastatic in 2001. disease during active therapy with CA27.29 or CA15-3 used in conjunction with diagnostic imaging, history, and physical examination has not changed. Updated 2007 Recommendations CEA Table A1 (online-only supplement; also available at CEA levels increase less commonly than MUC-1 levels. Data www.asco.org/guidelines/breasttm) presents a complete suggest that evaluating one of the MUC-1 assays and also CEA summary of the updated recommendations. initially in a patient with metastatic disease is reasonable. If the MUC-1 assay is elevated, monitoring CEA has no role, but if not, then CEA levels may provide supplementary clinical Breast Cancer Tumor Markers information for monitoring response to treatment as long as it is The panel considered evidence regarding 13 categories of breast done with clinical and radiographic investigations. tumor

Journal

Journal of Oncology PracticeWolters Kluwer Health

Published: Nov 1, 2007

References